Abstract

This program is concerned with the effects of biological response modifiers on cancer and on the immune and hematopoietic system. We will pursue two principal approaches - the study of agents whose primary action does not involve a specific immune response to cancer antigens, and the investigation of modalities that utilize current knowledge of cancer-specific antigens and of immune reactions directed against them. Agents to be investigated in the first category include interferons, thymic fractions, bacterial lipopolysaccharide and other bacterial products. In the second category, we will investigate the serological response to vaccines containing serologically defined cancer cell surface antigens, the possibility of augmenting the response by manipulations aimed at reducing suppressor cell activity, and the use of monoclonal antibodies against cancer cell surface antigens in diagnosis and therapy. The clinical program depends on, and is backed up by, extensive laboratory investigation.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA033049-06
Application #
3093496
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1982-07-01
Project End
1989-02-28
Budget Start
1987-08-01
Budget End
1989-02-28
Support Year
6
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021

  Publications

McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Alidori, Simone; Thorek, Daniel L J; Beattie, Bradley J et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS One 12:e0183902
Scheinberg, David A; Grimm, Jan; Heller, Daniel A et al. (2017) Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol 46:66-73
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Mathias, M D; Sockolosky, J T; Chang, A Y et al. (2017) CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia 31:2254-2257
Chang, Aaron Y; Gejman, Ron S; Brea, Elliott J et al. (2016) Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther 16:979-87
Alidori, Simone; Akhavein, Nima; Thorek, Daniel L J et al. (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 8:331ra39
Alidori, Simone; Bowman, Robert L; Yarilin, Dmitry et al. (2016) Deconvoluting hepatic processing of carbon nanotubes. Nat Commun 7:12343

Showing the most recent 10 out of 289 publications